Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease-Reference-Cited by-同舟云学术

Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease

Published:2024-01-05 Issue:4 Volume:95 Page:625-634
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Annals of Neurology

Author:

Vance Jeffery M.¹,Farrer Lindsay A.²³,Huang Yadong⁴,Cruchaga Carlos⁵^ORCID,Hyman Bradley T.⁶^ORCID,Pericak‐Vance Margaret A.¹,Goate Alison M.⁷,Greicius Michael D.⁸,Griswold Anthony J.⁹,Haines Jonathan L.¹⁰,TCW Julia¹¹¹²,Schellenberg Gerard D.¹³,Tsai Li‐Huei¹⁴,Herz Joachim¹⁵,Holtzman David M.¹⁶^ORCID

Affiliation:

1. John T. McDonald Department of Human Genetics, John P. Hussman Institute for Human Genomics University of Miami, Miller School of Medicine Miami FL USA

2. Departments of Medicine (Biomedical Genetics), Neurology and Ophthalmology Boston University Chobanian & Avedisian School of Medicine Boston MA USA

3. Departments of Epidemiology and Biostatistics Boston University School of Public Health Boston MA USA

4. Department of Neurology, Gladstone Center for Translational Advancement, Gladstone Institute of Neurological Disease University of California, San Francisco San Francisco CA USA

5. Department of Psychiatry Washington University in St. Louis St. Louis MO USA

6. Alzheimer Research Unit, Department of Neurology, The Massachusetts General Hospital Institute for Neurodegenerative Disease Harvard Medical School Boston MA USA

7. Departments of Genetics & Genomic Sciences Ronald M. Loeb Center for Alzheimer's disease, Icahn School of Medicine at Mount Sinai New York NY USA

8. Department of Neurology and Neurological Sciences Stanford University School of Medicine Stanford CA USA

9. John P. Hussman Institute for Human Genomics, The Dr. John T. Macdonald Foundation Department of Human Genetics University of Miami Miller School of Medicine Miami FL USA

10. Department of Population & Quantitative Health Sciences Case Western Reserve University Cleveland OH USA

11. Departments of Pharmacology, Physiology & Biophysics Chobanian & Avedisian School of Medicine Boston MA USA

12. Bioinformatics Program, Faculty of Computing & Data Sciences Boston University Boston MA USA

13. Department of Pathology and Laboratory Medicine Perelman School of Medicine, University of Pennsylvania Philadelphia PA USA

14. Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences Massachusetts Institute of Technology Cambridge MA USA

15. Departments of Molecular Genetics, Neuroscience, Neurology Center for Translational Neurodegeneration Research, UT Southwestern Dallas TX USA

16. Department of Neurology Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University in St. Louis St. Louis MO USA

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disorder and one of the leading causes of disability worldwide. The apolipoprotein E4 gene (APOE4) is the strongest genetic risk factor for AD. In 2023, the APOE4 National Institute on Aging/Alzheimer's Disease Sequencing Project working group came together to gather data and discuss the question of whether to reduce or increase APOE4 as a therapeutic intervention for AD. It was the unanimous consensus that cumulative data from multiple studies in humans and animal models support that lowering APOE4 should be a target for therapeutic approaches for APOE4 carriers. ANN NEUROL 2024;95:625–634

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ana.26864

Reference73 articles.

1. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

2. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

3. Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families

4. A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward

5. APOE Promoter Polymorphism-219T/G is an Effect Modifier of the Influence of APOE ε4 on Alzheimer’s Disease Risk in a Multiracial Sample

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates in Alzheimer's disease: from basic research to diagnosis and therapies;Translational Neurodegeneration;2024-09-04

2. Gene expression and chromatin accessibility comparison in iPSC-derived microglia in African, European, and Amerindian genomes in Alzheimer’s patients and controls;2024-08-27

3. A Framework for Best Practices and Readiness in the Advent of Anti-Amyloid Therapy for Early Alzheimer’s Disease in Asia;Journal of Alzheimer's Disease;2024-08-27

4. Multifaceted roles of APOE in Alzheimer disease;Nature Reviews Neurology;2024-06-21

5. Successful Gene Editing of Apolipoprotein E4 to E3 in Brain of Alzheimer Model Mice After a Single IV Dose of Synthetic Exosome-Delivered CRISPR;2024-04-28